A phase I trial of intravenous infusion of ONYX-015 and enbrel in solid tumor patients-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

A phase I trial of intravenous infusion of ONYX-015 and enbrel in solid tumor patients

Published:2007-08-17 Issue:11 Volume:14 Page:885-893
ISSN:0929-1903
Container-title:Cancer Gene Therapy
language:en
Short-container-title:Cancer Gene Ther

Author:

Nemunaitis J,Senzer N,Sarmiento S,Zhang Y-A,Arzaga R,Sands B,Maples P,Tong A W

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Molecular Biology,Molecular Medicine

Link

http://www.nature.com/articles/7701080.pdf

Reference24 articles.

1. O'Shea CC, Johnson L, Bagus B, Choi S, Nicholas C, Shen A et al. Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity. Cancer Cell 2004; 6: 611–623.

2. Nemunaitis J, Cunningham C, Buchanan A, Blackburn A, Edelman G, Maples P et al. Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity. Gene Therapy 2001; 8: 746–759.

3. Nemunaitis J, Cunningham C, Tong AW, Post L, Netto G, Paulson AS et al. Pilot trial of intravenous infusion of a replication-selective adenovirus (ONYX-015) in combination with chemotherapy or IL-2 treatment in refractory cancer patients. Cancer Gene Ther 2003; 10: 341–352.

4. Elkon KB, Liu CC, Gall JG, Trevejo J, Marino MW, Abrahamsen KA et al. Tumor necrosis factor alpha plays a central role in immune-mediated clearance of adenoviral vectors. Proc Natl Acad Sci USA 1997; 94: 9814–9819.

5. Peng Y, Trevejo J, Zhou J, Marino MW, Crystal RG, Falck-Pedersen E et al. Inhibition of tumor necrosis factor alpha by an adenovirus-encoded soluble fusion protein extends transgene expression in the liver and lung. J Virol 1999; 73: 5098–5109.

Cited by 69 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A PD-L1 tropism-expanded oncolytic adenovirus enhanced gene delivery efficiency and anti-tumor effects;International Immunopharmacology;2024-08

2. Identification of restrictive molecules involved in oncolytic virotherapy using genome-wide CRISPR screening;Journal of Hematology & Oncology;2024-05-23

3. Oncolytic Adenovirus for the Targeting of Paclitaxel-Resistant Breast Cancer Stem Cells;Viruses;2024-04-05

4. Tumor-targeted delivery of copper-manganese biomineralized oncolytic adenovirus for colorectal cancer immunotherapy;Acta Biomaterialia;2024-04

5. New hopes for the breast cancer treatment: perspectives on the oncolytic virus therapy;Frontiers in Immunology;2024-03-21

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3